Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Summary

In this episode of the Drive podcast, Peter Attia and his guest discuss two main topics related to type 2 diabetes. The first topic is GLP-1 agonists, a class of drugs that stimulate insulin release and inhibit glucagon release to reduce blood glucose and promote weight loss. The discussion includes the potential of GLP-1 agonists for weight loss beyond treating diabetes, with semiglutide and terzapatide being two drugs used for this purpose. Semiglutide is a pure GLP-1 agonist with a longer half-life and is dosed once a week, while terzapatide is a co-agonist of GIP and GLP-1 and has a potent GIP.

The second topic of discussion is metformin, a drug commonly used to treat type 2 diabetes. The hosts discuss how metformin reduces glucose production and its potential as a protective agent. The episode also touches on other drugs used to treat type 2 diabetes, such as SGLT2 inhibitors and sulfonylureas.

The hosts also discuss the increasing attention GLP-1 agonists are receiving and their personal experience with them in clinical settings. They mention that some people who are not overweight are interested in using GLP-1 agonists for weight loss for cosmetic reasons. However, it is important to note that GLP-1 agonists are not a magic pill for weight loss and should only be used under the guidance of a healthcare provider.

It is also mentioned that GLP-1 agonists are expensive and administered through pre-loaded pens that need to be refrigerated. While there is an oral version of semiglutide available for type 2 diabetes, it is also costly. The episode provides valuable information on GLP-1 agonists and metformin, their potential benefits, and their limitations in treating type 2 diabetes and promoting weight loss.